Citations

Clear

118 citation(s) found for "Bower, James".

Instrumented Walkway Gait Analysis Predicts Fallers in Neurological Disorders: Identifying Digital Biomarkers for Balance Monitoring
You, Sungmin , Barnard, Leland R , Jackson, Lauren , Bower, James H. , Klassen, Bryan T. , Elder, Benjamin D. , Graff-Radford, Jonathan, Howe, Charles L. , Ali, Farwa , You, Victor S , Klassen, Bryan T , Elder, Benjamin D , Howe, Charles L , Ali, Farwa , Botha, Hugo , Graff‐Radford, Jonathan

Mayo Clinic

Sensors | September 7, 2026 | Volume: 26 | Issue: 17 | Pages: 5644

10.3390/s26175644 | PMID 42740264 Get It

Assessing balance is crucial in neurological rehabilitation, yet while wearable sensors enable real-world monitoring, identifying reliable digital biomarkers remains challenging. This study utilized a high-fidelity instrumented walkway to determine which gait parameters best predict balance impairment, providing robust targets for future wearable applications. We analyzed 49 steady-state gait metrics from 140 individuals with diverse neurological conditions. Using statistical analysis and machine learning, we evaluated these parameters against objective force plate sway scores and clinical fall-history labels. Group analysis identified 16 parameters significantly distinguishing fallers from non-fallers, and a neural network classified fallers with an area under the curve of 0.75. Across all analytical approaches, overall gait variability, e.g., Stride Width S.D. and the Gait Variability Index, emerged as a universal predictor of balance impairment and fall risk. Furthermore, while traditional linear models emphasized spatial postural control, machine learning classification uniquely identified inter-limb asymmetry as a premier driver of fall prediction. These findings indicate that instrumented gait analysis effectively identifies digital biomarkers for balance deficits. Isolating these specific metrics provides a clear blueprint for meaningful metrics required for continuous objective monitoring and future development of personalized, adaptive rehabilitation strategies.
Cumulative incidence and risk factors of dementia in Parkinson's disease and parkinsonism: a population-based study
Malfer, Lorenzo , Lynott, Elena B. , Troxel, Colton , Ali, Farwa , Benarroch, Eduardo E. , Boeve, Bradley F. , Bower, James H, Savica, Rodolfo , Lynott, Elena , Boeve, Brad , Savica, Rodolfo , Mullan, Aidan F.

Mayo Clinic

Brain Communications | August 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/braincomms/fcag330 | PMID 42712997 Get It

Abstract Cognitive impairment is among the most common non-motor symptoms in parkinsonism and Parkinson’s disease, ranging from subjective complaints to dementia. Although several predictive factors have been described, their prognostic relevance remains uncertain. This study aims to examine the predictive association between clinical features and the risk of dementia and determine the incidence of dementia in a population-based cohort of incident parkinsonism cases. Patients with parkinsonism onset between 1991 and 2020 were identified using the Rochester Epidemiology Project records-linkage system. Subjects with cognitive impairment preceding motor symptoms onset or concomitant Alzheimer’s disease were excluded. Diagnoses of dementia and mild cognitive impairment were established using neuropsychological testing or brief cognitive screening. Development of dementia was assessed using a Cox proportional hazards regression model. Associations between dementia and each risk factor were individually estimated in adjusted Cox models. All risk factors were also included in a least absolute shrinkage and selection operator (LASSO) penalized multivariable Cox model. A total of 1,104 patients were included: 153 (13.9%) developed mild cognitive impairment and 543 (49.2%) developed dementia during follow-up. The cumulative incidence of dementia was 30.3% at 5 years, 48.6% at 10 years, 61.4% at 15 years, and 69.3% at 20 years, indicating that a considerable portion of patients remained free of dementia after a prolonged follow-up. The majority of patients with dementia were males (61.5%), and older age at disease onset was associated with risk of dementia (hazard ratio [HR] = 1.32, P < 0.001 per 5-year increment). In the penalized model, dementia risk was significantly higher among individuals presenting with impaired postural reflexes (HR = 1.26, P = 0.014), consistent with a poorer prognosis in akinetic-rigid-predominant parkinsonism. Eye movement abnormalities including reduced ocular range of motion (HR = 1.86, P < 0.001), and smooth pursuit alterations (HR = 1.34, P = 0.024) were also associated with dementia. Non-motor symptoms, including REM sleep behavior disorder (HR = 1.51, P < 0.001), orthostatic hypotension (HR = 1.30, P = 0.009), and constipation (HR = 1.24, P = 0.022), were linked to dementia risk, supporting a potential involvement of non-dopaminergic and central autonomic pathways in cognitive decline. These findings were largely confirmed in the Parkinson’s disease/Parkinson’s disease with dementia group, in which 77 (13.5%) developed mild cognitive impairment and 249 (43.5%) developed dementia. Among these patients, smooth pursuit alterations, reduced ocular range of motion, orthostatic hypotension, and constipation were associated with dementia.
White Matter Hyperintensity Association With Cognitive Impairment and Mortality in a Population-Based Cohort of Incident Parkinsonism
Malfer, Lorenzo , Mullan, Aidan F. , Camerucci, Emanuele, Turcano, Pierpaolo , Giorgi, Andrea, Yu, Jinna , Huston, John , Scharf, Eugene , Brown, Robert D. , Bower, James H. , Savica, Rodolfo , Huston, John , Scharf, Eugene L , Brown, Robert D , Mullan, Aidan , Camerucci, Emanuele , Yu, Jinna

Mayo Clinic

Neurology Open Access | August 18, 2026 | Volume: 2 | Issue: 3 | Pages: No page available

10.1212/wn9.0000000000000151 Get It

Juvenile Parkinson's disease: Symptom burden and treatment challenges
Malfer, Lorenzo , Piat, Capucine , Uitti, Ryan J., Fugoso, Leonardo G., Bower, James H. , Savica, Rodolfo , Coffman, Keith A, Savica, Rodolfo , Mullan, Aidan F. , Uitti, Ryan J. , Fugoso, Leonardo, Coon, Elizabeth A. , Coffman, Keith A.

Mayo Clinic

Journal of Parkinson’s Disease | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/1877718x261473047 | PMID 42555091 Get It

Juvenile Parkinson's disease (JPD) is a rare condition characterized by the onset of parkinsonian motor symptoms before the age of 21. Sixteen patients with JPD who presented to the Mayo Clinic between 1990-2020 were included. The median age of symptoms onset was 18.5 years, and six cases had pathogenic PRKN mutations. Resting tremor was the most frequent initial symptom (81.3%), and non-motor symptoms were notably common, including mild cognitive impairment (56.3%), anxiety (62.5%), and depression (56.3%). Levodopa responsiveness was suboptimal in 9 patients and 14 exhibited motor fluctuations. JPD demonstrates distinct clinical characteristics compared with early-onset and late-onset PD.
Familial Aggregation of Parkinson Disease and Essential Tremor in Early and Late Onset Parkinson Disease Cohorts
Malfer, Lorenzo , Liu, Tina , Mullan, Aidan F. , Santoro, Emanuela , Lynott, Elena B. , Troxel, Colton E. , Derhab, Mohamed , Ghoniem, Khaled , Ross, Owen A. , Bower, James H. , Savica, Rodolfo , Mullan, Aidan , Ross, Owen A , Lynott, Elena , Troxel, Colton

Mayo Clinic

Neurology | July 1, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000218315 | PMID 42385114 Get It

Predictive Risk Factors of Cognitive Impairment and Dementia in a Population-based Cohort of Incident Parkinsonism in Olmsted County (P3-16.015)
Malfer, Lorenzo , Lynott, Elena, Mullan, Aidan, Santoro, Emanuela , Troxel, Colton , Bower, James, Savica, Rodolfo, Lynott, Elena B. , Mullan, Aidan F. , Savica, Rodolfo

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215343 Get It

Neuropsychiatric Features of Parkinson’s Disease And Parkinsonism: A Population-based Study 1991–2020 (P3-16.003)
Santoro, Emanuela , Mullan, Aidan, Malfer, Lorenzo , Bower, James, Savica, Rodolfo, Mullan, Aidan F. , Derhab, Mohamed , Savica, Rodolfo

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213152 Get It

Long‐Term Outcomes in Stiff Person Spectrum Disorder
Mangioris, Georgios , McKeon, Andrew, Bower, James H. , Vorasoot, Nisa , Dubey, Divyanshu, Flanagan, Eoin P., Pittock, Sean J., Ζεκερίδου, Αναστασία , Zekeridou, Anastasia , Vorasoot, Nisa , McKeon, Andrew , Dubey, Divyanshu , Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

European Journal of Neurology | May 22, 2026 | Volume: 33 | Issue: 5 | Pages: No page available

10.1111/ene.70609 | PMID 42171443 Get It

ABSTRACT Background Long‐term outcome data for stiff person spectrum disorder (SPSD) remain limited and sustained response to treatment varies. Methods In this retrospective cohort study, we included patients with probable or definite SPSD (Mayo Clinic criteria), evaluated at Mayo Clinic (12/1995‐07/2024) with ≥ 5 years of follow‐up after diagnosis. Primary outcome measures included the modified Rankin scale (mRS) and use of gait aids. Results Fifty‐four patients were included, 41 (76%) were female; median age at onset was 45 years (16–78). Most were antibody‐positive (51 [94%]), with high‐titer (serum, ≥ 20 nmol/L) GAD65‐IgG in 45 (83%). Nine patients had a stiff‐limb presentation (17%). The median interval from onset to diagnosis was 2 years (0–34), and median follow‐up was 9 years (5–26). Most patients (46 [85%]) received immune therapy; 37 (82%) reported improvement. All patients had significant impairment (mRS ≥ 2) at nadir, with 31 (57%) losing functional independence (mRS ≥ 3) and 40 (75%) requiring bilateral gait assistance. The median time from onset to nadir was 6 years (0–39). At last follow‐up, most (37 [69%]) were functionally independent (mRS ≤ 2), including 8 (15%) with minimal restrictions (mRS ≤ 1). Bilateral gait assistance was needed in 22 (41%). Among 40 patients with ≥ 10 years of follow‐up, 22 (56%) had an mRS ≤ 2 and 25 (63%) required a gait aid at last follow‐up. Poor outcome in this population was associated with bilateral gait assistance at nadir and older age ( p < 0.05). Conclusions Although over half of SPSD patients lose functional independence at disease nadir, many regain independence and achieve well‐controlled symptoms.
Autonomic Dysfunction and Risk of Mortality in Early‐Onset Parkinson's Disease
Piat, Capucine , Ghoniem, Khaled , Turcano, Pierpaolo , Camerucci, Emanuele, Benarroch, Eduardo E. , Cutsforth‐Gregory, Jeremy K. , Bower, James H., Savica, Rodolfo, Savica, Rodolfo , Mullan, Aidan F. , Camerucci, Emanuele , Savica, Rodolfo

Mayo Clinic

Annals of Neurology | December 31, 2025 | Volume: 99 | Issue: 4 | Pages: 964-975

10.1002/ana.78143 | PMID 41474120 Get It

Objective Dysautonomia affects many patients with Parkinson's disease and correlates with increased cardiovascular mortality. We describe the frequency and onset time of autonomic dysfunction relative to disease onset in early‐onset Parkinson's disease (EOPD) and explore its association with mortality. Methods We identified all incident Parkinson cases with motor‐symptom onset before age 50 years evaluated at the Mayo Clinic Health System (1990–2022) including sex‐ and age‐matched controls for each patient. Medical record review confirmed clinical diagnosis and assessed the presence and onset of autonomic symptoms, relative to Parkinson onset. Results We included 829 patients with EOPD and 829 healthy controls. The median age at disease onset was 42 years (interquartile range [IQR] = 37–46 years). Autonomic symptoms were present in 63.4% of patients, compared with 27.0% of unaffected controls, and proceeded motor symptoms in 91.4%. Forty‐seven percent of patients with early‐onset Parkinson's disease had constipation, 27.4% had bladder urgency, 19.3% had orthostatic intolerance, and 15.4% had sweat dysfunction. Among male patients, 36.8% had erectile dysfunction. In our EOPD population only, the presence of any autonomic‐impairment symptoms correlated with a 2.71‐fold increased mortality risk; each additional reported symptom increased the relative mortality risk by 50% ( p < 0.001). Patients with constipation or orthostatic intolerance had a 3.22‐ and 2.78‐fold higher mortality than patients without these symptoms. Interpretation Autonomic impairment affects 63.4% of patients with EOPD and carries a 3‐fold higher mortality risk, which increases with every additional autonomic symptom reported. In our cohort, autonomic symptoms appeared most commonly after motor onset, contrasting with prodromal autonomic impairment seen in late‐onset Parkinson's disease (LOPD). ANN NEUROL 2026;99:964–975
Psychosis in early onset Parkinson's disease: A retrospective cohort study in southeast Minnesota
Derhab, Mohamed , Mullan, Aidan F. , Turcano, Pierpaolo , Camerucci, Emanuele, Piat, Capucine , Ghoniem, Khaled , Bower, James H., Savica, Rodolfo , Dehnavi, Ali Zare, Savica, Rodolfo , Mullan, Aidan , Camerucci, Emanuele , Dehnavi, Ali Zare

Mayo Clinic

Journal of Parkinson’s Disease | July 1, 2025 | Volume: 15 | Issue: 6 | Pages: 1078-1085

10.1177/1877718x251354978 | PMID 40589144 Get It

Background Early onset Parkinson's disease (EOPD), defined as Parkinson's disease (PD) diagnosed before age 50, often presents unique challenges compared to late-onset PD, particularly with regard to non-motor symptoms. Psychosis in EOPD is associated with increased functional impairment and may lead to a higher mortality risk. Objective Our study is aimed to determine the prevalence of psychosis in EOPD patients and its impact on all-cause mortality, along with examining the effects of antipsychotic medications and Selective Serotonin Reuptake Inhibitors (SSRIs) on mortality in EOPD patients. Methods Our retrospective cohort included EOPD patients diagnosed between 1990 and 2022 at Mayo Clinic, Rochester, Minnesota. Psychosis was defined using the National Institute of Neurological Disorders and Stroke/the National Institute of Mental Health (NINDS/NIMH) Work Group criteria. Cox proportional hazards models were used to analyze the association of psychosis and medications with mortality. Results Of 829 patients with EOPD, 158 (19.1%) developed psychosis at a median of 12.1 years after PD motor symptom onset. Psychosis was significantly associated with increased mortality in unadjusted (HR = 4.31, 95% CI: 2.59–7.18, p < 0.001) and adjusted (HR = 3.55, 95% CI: 2.10–6.01, p < 0.001) models. No significant difference in mortality risk was observed between patients treated with antipsychotics or SSRIs versus those who were not. Conclusions Psychosis is a possible complication in EOPD and is associated with a significant increase in all-cause mortality. The use of antipsychotics and SSRIs did not significantly alter the mortality risk in these patients. Further research is needed to understand the mechanisms driving this association and to develop tailored interventions.